NB: this is a summary translation of the press release original drafted in Japanese for the disclosure required in compliance with the TSE regulations.

February 18, 2021

Oncolys BioPharma Inc.

Announcement of International Nonproprietary Name for Telomelysin (OBP-301)

Oncolys BioPharma Inc. (hereafter, "Oncolys") today announced that the World Health Organization selected the recommended International Nonproprietary Name (INN) for "Telomelysin (OBP-301)", oncolytic viral immunotherapy.

International nonproprietary name of Telomelysin (OBP-301): **suratadenoturev**

Decision of the INN by WHO is an important step towards obtaining approval of a new drug, and the name, suratadenoturev will be used for Telomelysin in the world.
The registration procedures in the United States (USAN: United States Adopted Names) will be followed.

Oncolys develops Telomelysin based on the concept of "cure without surgery".
Oncolys will promote research and development on the combination of Telomelysin and other treatments and aims to contribute to the development of cancer treatments that will help in the medical field.

The announcement above will not affect Oncolys' earnings for the fiscal year ending December 31, 2021.

Ends

###

About Oncolys BioPharma Inc.
Oncolys BioPharma develops novel cancer therapeutics and diagnostic products using gene modified viral technologies and aims to contribute to fulfill unmet medical needs for cancer and severe infectious diseases. Especially in oncology area, we utilize technology platform for oncolytic virus and develop Telomelysin and its next-generations for cancer treatment and TelomeScan for early detection of cancer and recurrence monitoring after surgery. We have established broad range of product pipeline to cover early detection of cancer, early treatment of local cancer, post-operative examination, and treatment of metastatic cancer. For more information, please visit http://www.oncolys.com/en/

Oncolys BioPharma Inc.
Email: oncolys_information@oncolys.com

TRANSLATION